Biomarker-Guided Antidepressants — PatSnap Eureka
Biomarker-Guided Antidepressant Pipeline: Precision Psychiatry & Triple Reuptake Inhibitor Approaches
Major depressive disorder affects millions who fail first-line SSRI/SNRI therapy. Discover how pharmacogenomic biomarkers, triple reuptake inhibitors, and kappa-opioid receptor antagonism are reshaping the antidepressant pipeline — from patent filings to clinical signals.
From Trial-and-Error to Biology-Driven Prescribing in MDD
Major depressive disorder (MDD), treatment-resistant depression (TRD), and related psychiatric conditions — including bipolar disorder, suicidality, PTSD, and schizophrenia — form the primary disease contexts in this patent dataset. According to WHO, depression is a leading cause of global disability, making the unmet need for precision treatment approaches acute.
The molecular target landscape is heterogeneous, spanning multiple neurotransmitter systems. Monoamine systems remain central: retrieved patents identify serotonin (5-HT) reuptake transporters, norepinephrine transporters, and dopamine transporters as co-inhibition targets for triple reuptake inhibitors. The PatSnap analytics platform enables systematic mapping of these overlapping target clusters across global patent families.
Beyond monoamines, the kappa-opioid receptor (KOR) is implicated by Janssen's aticaprant patents, linking KOR antagonism to a defined biomarker signature in MDD patients with prior inadequate SSRI/SNRI response. Glutamatergic/NMDA pathways are addressed via GABR-A2 SNP-based patient stratification for NMDA antagonists including ketamine. The vasopressin/CRH stress axis is targeted through AVPR1B gene polymorphisms (SNP rs28373064) as predictors of V1B antagonist response, as described in Max-Planck-Gesellschaft filings.
Emerging targets include circadian clock Per gene CRE sequence mutations/epigenetic modifications (University of Chinese Academy of Sciences), TAAR1/5-HT1A co-agonism (Sumitomo's ulotaront), and gut microbiome metabolite integration for dynamic dosing (Beijing Huilongguan Hospital, 2025). These represent a decisive shift beyond classical monoamine pharmacology, tracked in depth via PatSnap's life sciences intelligence suite.
Seven Precision Psychiatry Approaches Shaping the Antidepressant Pipeline
From triple reuptake inhibitors with pharmacogenomic companion diagnostics to blood gene expression panels for suicidality — each modality represents a distinct IP cluster and clinical strategy.
Triple Reuptake Inhibitors with Companion Diagnostics
DeNovo Biopharma's liafensine (DB1/DB104) simultaneously inhibits serotonin, norepinephrine, and dopamine transporters. Described as developed to "synergize the individual, though complementary, monoaminergic treatments for depression to maximize antidepressant efficacy and tolerability." The compound completed multiple Phase 2 studies in TRD before discontinuation; DeNovo's IP strategy now pivots to pharmacogenomic biomarkers to identify the responsive sub-population. Euthymics' EB-1010 provides a second TRI scaffold, with Phase 2 data indicating no sexual dysfunction signal.
Phase 2 completed · Biomarker re-stratification proposedKappa-Opioid Receptor Antagonism (Aticaprant, Janssen)
Janssen Pharmaceuticals' aticaprant filings represent the clearest example of a fully biomarker-gated MDD therapy in this dataset. Patient eligibility requires a positive biomarker signature, specifically addressing patients with inadequate SSRI/SNRI response. The US 2025 patent references patients with "inadequate response to other antidepressant therapy," with a defined "biomarker signature positive" eligibility criterion. Multi-jurisdictional filings (WO 2023, US 2025, CA) signal global commercial intent and an active patent moat around KOR antagonism in biomarker-positive MDD.
Clinical stage · WO/US/CA filings 2023–2025NMDA/Glutamate Receptor Modulators with SNP-Based Patient Selection
AstraZeneca's GABR-A2 filings focus on four SNPs in the GABA-A receptor alpha-2 subunit to predict response to NMDA antagonists including ketamine and (S)-1-phenyl-2-(pyridin-2-yl)ethanamine. The University of Michigan extends pharmacogenomic decision support to NMDA, glycine receptor beta (GLRB), and AMPA receptor modulators, incorporating SNP panels and ketamine-specific topological association domain analysis — representing an emerging computational pharmacogenomics direction. Both institutions' filings cover distinct molecular layers of the glutamatergic system.
Preclinical/translational · Ketamine as benchmarkTAAR1/5-HT1A Agonism (Ulotaront) as Augmentation
Sumitomo Pharma America's filings describe ulotaront, a trace amine-associated receptor 1 (TAAR1) and 5-HT1A agonist, as an augmentation agent for inadequate antidepressant responders. Retrieved text describes preclinical antidepressant behavioral activity in rat models that "many conventional antidepressants are unable to treat." The CN 2025 patent references a large randomized, double-blind, placebo-controlled clinical trial demonstrating efficacy in schizophrenia exacerbation. The MDD augmentation indication is described as a new finding from preclinical rat models, suggesting IND-stage or earlier for MDD specifically.
Clinical (schizophrenia) · MDD augmentation preclinicalMetabolomic Biomarker Diagnostics for Depression & Treatment Monitoring
Multiple patent families (Dunlop/Jia Wei/Krishnan/Rush Medical College) cover a metabolomic biomarker suite spanning acylcarnitines (C3, C5), alpha-aminoadipate, and other plasma/serum metabolites. These are positioned to evaluate likelihood of SSRI/SNRI response and guide treatment switching. Specific antidepressants cited include escitalopram, citalopram, fluoxetine, sertraline, vortioxetine, and duloxetine, assessed using validated instruments HRSD17 and QIDS. Filed across CA, WO, IL, AU, US, and JP jurisdictions by an academic inventor consortium.
Diagnostic/translational · Multi-jurisdiction prosecutionBlood Gene Expression Panels for Suicidality & Drug Repurposing
Indiana University Research and Technology Corporation and the US Department of Veterans Affairs have filed an extensive precision psychiatry patent series using blood gene expression panels (SAT1, FOXN3, GBP1, PIK3R5, APOL2, MARCKS, GCOM1) to stratify suicidality risk, identify treatment candidates, and repurpose existing compounds. Algorithms combine biomarkers with clinical measures for universal and gender/diagnosis-personalized predictions. The academic paper describes a "liquid biopsy" approach validated across multiple clinical cohorts using stepwise discovery, prioritization, and validation methodology.
Translational · US/WO/CA filings 2014–2024Key Targets & Assignee Activity: What the Patent Data Reveals
Visualising pharmacological target coverage and organisational IP activity across the biomarker-guided antidepressant pipeline dataset.
Pharmacological Target Coverage by Filing Intensity
DAT/SERT/NET triple transporters and KOR (aticaprant) represent the highest filing intensity in this dataset, reflecting commercial-stage IP prosecution by DeNovo Biopharma and Janssen respectively.
Key Assignee Patent Activity Timeline (2012–2025)
Patent filing activity across the primary precision psychiatry assignees, showing the field's progression from early diagnostic platforms (Genomind 2012–13) to recent commercial biomarker-gated drug patents (Janssen 2023–25, Sumitomo 2025).
Who Owns the Precision Psychiatry Patent Space?
Patent-driven activity predominates in this dataset. Commercial pharma, academic-government clusters, and diagnostic platform companies each occupy distinct IP positions.
Conduct Freedom-to-Operate Analysis on KOR Antagonist Claims
Janssen's multi-jurisdictional aticaprant + biomarker signature filings (WO/US/CA, 2023–2025) establish a strong IP position. Use PatSnap Eureka to assess claim scope before entering this space.
What This Patent Landscape Means for Drug Developers & IP Teams
Five actionable intelligence signals derived directly from the precision psychiatry patent dataset.
Pharmacogenomic Biomarkers Are Now an Expected Co-Development Component
In this dataset, the TRI liafensine and the KOR antagonist aticaprant both rely on genomic/molecular biomarkers to define eligible patient populations. Drug developers working in this space should anticipate that biomarker companion diagnostic co-development is now an expected component of regulatory and commercial strategy, not an add-on. Explore PatSnap's life sciences intelligence for companion diagnostic landscape analysis.
Failed Phase 2 Trials May Contain Recoverable Signals
DeNovo Biopharma's explicit strategy of applying pharmacogenomics to a Phase 2 TRI failure is a replicable model. IP teams should evaluate whether retrospective biomarker analysis of prior negative MDD trials in DAT/NET/SERT-targeting compounds could unlock value. According to NIH research on treatment-resistant depression, stratified re-analysis of failed trials has yielded actionable sub-population signals in other CNS indications.
KOR Antagonism Has an Active Patent Moat Requiring FTO Analysis
Janssen's multi-jurisdictional aticaprant + biomarker signature filings (WO/US/CA, 2023–2025) establish a strong IP position around KOR antagonism in biomarker-positive MDD. New entrants to KOR antidepressant development should conduct freedom-to-operate analysis against these biomarker-linked claim sets. The PatSnap analytics platform enables systematic claim mapping.
Glutamatergic Precision Psychiatry Spans Differentiated IP Layers
AstraZeneca's GABR-A2 and the University of Michigan's NMDA/AMPA/GLRB pharmacogenomic decision support filings cover distinct molecular layers of the glutamatergic system. Both ketamine-derivative programs and novel NMDA-adjacent programs may benefit from licensing or cross-referencing these SNP panels in clinical development design. Review patent families via EPO and PatSnap Eureka for claim scope assessment.
Seven Convergence Strategies Shaping Next-Generation Antidepressant Development
TRI + Pharmacogenomics: DeNovo Biopharma's filings signal a strategy of using genomic biomarker panels to identify the TRI-responsive subpopulation within the MDD continuum — a paradigm of rescuing failed broad-population trials through retrospective/prospective biomarker stratification. This approach is directly applicable to other discontinued DAT/NET/SERT-targeting compounds in industry pipelines.
KOR Antagonist + Prior SSRI/SNRI Failure as Enrichment Criterion: Janssen's aticaprant patents define the clinical combination (SSRI/SNRI inadequate response → KOR antagonist) and use biomarker signature as an enrollment gate, signaling the convergence of pharmacogenomics with adjunctive depression therapy. This represents a template for other adjunctive antidepressant programs targeting treatment-resistant populations, as tracked by ClinicalTrials.gov.
NMDA Antagonist + Multi-Receptor SNP Panel: University of Michigan filings extend beyond single-gene pharmacogenomics to multi-SNP panels combined with topological association domain analysis for ketamine-adjacent therapies, representing an emerging computational pharmacogenomics direction. PatSnap customers in CNS drug discovery have used similar multi-SNP landscape analysis to prioritise licensing targets.
Antidepressant + Dopamine D1 Receptor Agonist Combination: A Japanese patent from Nippon Medical School describes combining antidepressants with dopamine D1 receptor agonists to enhance depression-related gene expression as a combinatorial strategy. Gut Microbiome Metabolite Monitoring for Dynamic Dosing: A 2025 Chinese patent from Beijing Huilongguan Hospital describes a system integrating gut microbiota metabolite monitoring (short-chain fatty acids) with antidepressant drug metabolism kinetics for real-time dose adjustment — an emerging computational-biological convergence direction tracked through PatSnap's open API.
EEG + Genomic Biomarker Co-Selection: Ortho Neuroscience's NSI-189 filings describe EEG characteristics alongside genetic biomarkers for patient selection, suggesting a multimodal precision approach combining neurophysiology with genomics for cognitively impaired depressed patients across MDD, bipolar disorder, PTSD, and schizophrenia-related depression.
Biomarker-Guided Antidepressants — Key Questions Answered
A triple reuptake inhibitor simultaneously inhibits serotonin, norepinephrine, and dopamine transporters. Liafensine (DB1/DB104), developed by DeNovo Biopharma, is described as an inhibitor of all three neurotransmitter transporters, developed to synergize the individual, though complementary, monoaminergic treatments for depression to maximize antidepressant efficacy and tolerability. SSRIs target only the serotonin transporter, while SNRIs target serotonin and norepinephrine. A key differentiation cited for the TRI EB-1010 (Euthymics Bioscience) is that Phase 2 data indicate the drug does not cause sexual dysfunction, a common SSRI side effect.
Liafensine (also referred to as DB104 and DB1) completed multiple Phase 2 clinical studies in treatment-resistant depression. The program was discontinued after Phase 2 based on overall population results. DeNovo Biopharma's pharmacogenomic biomarker strategy is positioned as the mechanism to enable a re-stratified Phase 2 or Phase 3 attempt by identifying the sub-population most likely to respond.
Janssen Pharmaceuticals' filings on aticaprant represent the clearest example of a fully biomarker-gated MDD therapy. The mechanism is kappa-opioid receptor (KOR) antagonism; patient eligibility requires a positive biomarker signature. The filings specifically address patients with inadequate SSRI/SNRI response, positioning aticaprant as an adjunctive or subsequent-line agent. The US 2025 patent references patients with inadequate response to other antidepressant therapy including SSRIs and SNRIs, with a defined biomarker signature positive eligibility criterion.
Multiple patent families cover a metabolomic biomarker suite for MDD diagnosis and treatment response monitoring, spanning acylcarnitines (C3, C5), alpha-aminoadipate, and other metabolites. These are positioned to evaluate likelihood of SSRI/SNRI response and to guide treatment switching. Specific antidepressants cited include escitalopram, citalopram, fluoxetine, sertraline, vortioxetine, and duloxetine. Validated depression rating instruments HRSD17 and QIDS are referenced for quantitative assessment.
Indiana University Research and Technology Corporation and the US Department of Veterans Affairs have filed precision psychiatry patents using blood gene expression panels including SAT1, FOXN3, GBP1, PIK3R5, APOL2, MARCKS, and GCOM1 to stratify suicidality risk, identify treatment candidates, and repurpose existing compounds. Algorithms combine biomarkers with clinical measures for universal and gender/diagnosis-personalized predictions. Decrease in expression post-treatment is described as a response signal.
Retrieved filings signal several emerging directions beyond SSRIs/SNRIs/TRIs: TAAR1 agonism (Sumitomo's ulotaront, a TAAR1/5-HT1A co-agonist with non-D2 mechanism); circadian clock Per gene CRE epigenetic markers (University of Chinese Academy of Sciences); gut microbiome metabolite monitoring for dynamic antidepressant dosing (Beijing Huilongguan Hospital, 2025); and EEG plus genomic biomarker co-selection (Ortho Neuroscience's NSI-189 filings). These represent early but active IP claims in mechanistically novel antidepressant directions.
Still have questions about the precision psychiatry patent landscape? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka Your Research QuestionsAccelerate Your Precision Psychiatry Drug Discovery with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map biomarker IP landscapes, identify assignee activity, and conduct freedom-to-operate analysis across the antidepressant pipeline.
References
- Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters — DeNovo Biopharma LLC, 2022 [Patent, IL]
- Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters — DeNovo Biopharma LLC, 2022 [Patent, IL]
- Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters — DeNovo Biopharma LLC, 2023 [Patent, JP]
- Compositions and methods for the treatment of depression — Janssen Pharmaceuticals, Inc., 2025 [Patent, US]
- Compositions and methods for the treatment of depression — Janssen Pharmaceuticals, Inc., 2023 [Patent, WO]
- GABR-A2 diagnosis — AstraZeneca Aktiebolag, 2015 [Patent, JP]
- Pharmacogenomic decision support for modulators of NMDA, glycine and AMPA receptors — The Regents of the University of Michigan, 2024 [Patent, JP]
- Method for predicting a treatment response to a V1B antagonist — Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 2019 [Patent, EP]
- Blood biomarkers for suicidality — Indiana University Research & Technology Corporation, 2016 [Patent, US]
- Precision medicine for treating and preventing suicidality — US Department of Veterans Affairs, 2020 [Patent, US]
- Precision medicine for suicidality: from universality to subtypes and personalization — Niculescu et al., 2017 [Paper]
- Methods and compositions for diagnosing depression — Boadie W. Dunlop, 2020 [Patent, CA]
- Ulotaront for adjunctive treatment of major depressive disorder — Sumitomo Pharma America, Inc., 2025 [Patent, CN]
- Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane — Euthymics Bioscience, Inc., 2012 [Patent, CA]
- Major-effect markers influencing depressive or antidepressant behavior and their applications — University of Chinese Academy of Sciences [Patent]
- Methods for treating depressed patients with poor cognition and selection of other patients who would benefit from benzylpiperazine-aminopyridine drugs — Ortho Neuroscience, 2024 [Patent, JP]
- A method and device for dynamic adjustment of antidepressant dosage based on gut microbiota metabolite monitoring — Beijing Huilongguan Hospital, 2025 [Patent, CN]
- Neuropsychiatric test reports — Genomind, LLC, 2013 [Patent, WO]
- World Health Organization (WHO) — Depression Fact Sheet
- National Institutes of Health (NIH) — Treatment-Resistant Depression Research
- ClinicalTrials.gov — Precision Psychiatry Clinical Trial Registry
- European Patent Office (EPO) — Patent Family Search
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.